• For US Healthcare Professionals
  • For Patients and Caregivers
A A A


Patient Education >   En Español >  Call (877) 436-3683

  • US Healthcare Professionals
  • How We Help You
    • Patient Navigators
  • Forms & Documents
  • FAQs

Patient Education >

 

En Español >

 

Call (877) 436-3683

  • ACTEMRA® (tocilizumab)‎
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COTELLIC® (cobimetinib)
  • ENSPRYNG™ (satralizumab-mwge)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • Evrysdi™ (risdiplam)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PERJETA® (pertuzumab)
  • PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
  • POLIVY® (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK™ (entrectinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • XELODA® (capecitabine)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)
  • ONCOLOGY
  • RHEUMATOLOGY

Please select a treatment to continue

  • ACTEMRA® (tocilizumab)‎
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COTELLIC® (cobimetinib)
  • ENSPRYNG™ (satralizumab-mwge)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • Evrysdi™ (risdiplam)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PERJETA® (pertuzumab)
  • PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
  • POLIVY® (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK™ (entrectinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • XELODA® (capecitabine)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)
  • Or Select

  • ONCOLOGY
  • RHEUMATOLOGY

Please select a treatment to continue

Select a disease state for Rituxan® (rituximab)

  • Rituxan® (rituximab) for Rheumatoid Arthritis (RA)
  • Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
  • RITUXAN® (rituximab) for Oncology
  • Rituxan® (rituximab) for Pemphigus Vulgaris (PV)

Site Map

How We Help You
Patient Navigators
Forms & Documents
FAQs

We are here to help.

Call 866-422-2377

2021
  • Contact Us
  • Site Map
  • Privacy Policy
  • Terms & Conditions
  • Cookie Preferences

©[YEAR] Genentech USA, Inc.  All rights reserved.  This site is intended for US residents only.

The Access Solutions logo is a registered trademark of Genentech, Inc.

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel OK

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

Cancel OK

Cancel

Your email has been sent!

Thanks for sharing this page.